Location Directory

Clinical trials in Nashville, Tennessee

This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

4964

Shown on this page

Local exact-city summaries

4964

Based on exact city/state matches in the local index.

Local exact-city recruiting

997

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for Nashville, Tennessee. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 4,964 matching trials in Nashville, TN.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for Nashville, TN. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Breast Cancer 186 Colorectal Cancer 115 Melanoma 93 Multiple Myeloma 90 Ovarian Cancer 83 Cancer 79

Top sponsors in local exact-city summaries

Vanderbilt University Medical Center 389 National Cancer Institute (NCI) 229 Children's Oncology Group 147 Hoffmann-La Roche 128 Vanderbilt University 120 Pfizer 118

Top therapies in local exact-city summaries

Carboplatin 157 Pembrolizumab 147 Cyclophosphamide 132 Paclitaxel 118 Gemcitabine 108 Cisplatin 103

Indexed official records

Open in full search

Conditions: Distal Esophageal Spasm, EGJ Outflow Obstruction With Spastic/Hypercontractile Features, Jackhammer Esophagus, Type III Achalasia
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 10 more

Conditions: EGJ Outflow Obstruction Without Spastic/Hypercontractile Features, Type I Achalasia, Type II Achalasia
Interventions: Standard Myotomy, Tailored Short Myotomy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 10 more

Conditions: Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 152
States / cities: Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 124 more

Conditions: Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions: Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 187
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 149 more

Conditions: Endometrial Cancer, Malignant Solid Tumour
Interventions: Doxorubicin, Paclitaxel, Puxitatug Samrotecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 66
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more

Conditions: FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, Low-grade NMIBC
Interventions: TYRA-300 50mg, TYRA-300 60mg, TYRA-300 Dose TBD; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more

Conditions: Castration-resistant Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Interventions: DCC-2812; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 2 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin hydrochloride, Epirubicin hydrochloride, Olaparib, Paclitaxel, Patritumab deruxtecan, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 8
States / cities: Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Cyclophosphamide, Methotrexate (MTX), Mycophenolate mofetil (MMF), Ruxolitinib (Rux), Tacrolimus (Tac); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 30
States / cities: Palo Alto, California • San Francisco, California • Miami, Florida + 23 more

Conditions: Colorectal Cancer
Interventions: Fruquintinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more

Conditions: Untreated Follicular Lymphoma
Interventions: Surovatamig, R-CHOP, R-CVP, BR
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 51
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 45 more

Conditions: Large B-cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, cemacabtagene ansegedleucel; Drug · Device · Genetic
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 47 more

Clinical trials in Nashville, Tennessee

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

PREcision MEDicine In Achalasia (PREMEDIA) - Cohort

PREcision MEDicine In Achalasia (PREMEDIA)

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL